Adjuvant Carboplatin and Gemcitabine Combination Chemotherapy Postamputation in Canine Appendicular Osteosarcoma

Journal of Veterinary Internal Medicine

M. McMahon²  T. Mathie⁴  N. Stingle⁴  E. Romansik³  D. Vail¹ 

[1] Department of Medical Sciences, School of Veterinary Medicine, The Carbone Comprehensive Cancer Center, University of Wisconsin—Madison, Madison, WI;Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH;New England Veterinary Oncology Group, Waltham, MA;Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH

关键词: Bone cancer;    Chemotherapy;    Dog;    Oncology;   

DOI  :  10.1111/j.1939-1676.2011.0697.x

来源: Wiley

【 摘 要 】

Abstract

Background: Appendicular osteosarcoma (OSA), the most common bone tumor in dogs, is typically treated by amputation and adjuvant chemotherapy. Despite numerous efforts, the median survival time (MST) for dogs receiving a platinum compound, doxorubicin, or a combination of these remains at 8–12 months. Evidence from studies in mice suggests that gemcitabine has activity against OSA in vivo. Our preliminary work demonstrated that the addition of low-dosage (10 mM) gemcitabine to carboplatin resulted in synergistic inhibition of OSA cell viability in vitro.

Objective: The purpose of the following study was to determine whether the addition of low-dosage (2 mg/kg) gemcitabine to carboplatin chemotherapy in dogs with OSA after amputation would improve MST over carboplatin monotherapy.

Animals: Fifty dogs with histologically confirmed appendicular OSA.

Methods: Dogs were treated prospectively with amputation and up to 4 dosages of carboplatin and gemcitabine in combination every 3 weeks.

Results: The chemotherapeutic regimen was well tolerated with only 5 episodes of grade 3 or 4 hematologic toxicity. The median disease-free interval (DFI) was 203 days and the MST was 279 for all dogs in this study. The 1- and 2-year survival rates were 29.5 and 11.3%, respectively. Dogs with proximal humeral OSA had a shorter median DFI (P= .04) compared with dogs with OSA in other locations.

Conclusions and Clinical Importance: These results are comparable to those reported for carboplatin monotherapy indicating that the addition of gemcitabine to carboplatin in dogs with appendicular OSA does not appear to improve outcome.

【 授权许可】

Unknown   
Copyright © 2011 by the American College of Veterinary Internal Medicine